India’s Directorate General of Trade Remedies has recommended anti-dumping duties on certain medical examination rubber gloves imported from Malaysia and Thailand. The proposed rates range from $288 to $565 per 100,000 pieces, depending on the producer and country.
Cover: an original AI-generated editorial illustration of medical examination gloves and supply cartons.
Breakdown
The DGTR’s final findings, published on November 6, recommend $442 per 100,000 pieces for Malaysia’s YTY and $565 for other Malaysian producers. For Thailand, the proposed rate is $288 for Sri Trang and $486 for other producers, subject to the origin, export and producer combinations in the duty table.
The producer-specific rates require the qualifying commercial-invoice declaration set out in the findings. These are fixed dollar amounts for a specified quantity, not percentage tariffs. The recommendation is for five years from publication of a future Central Government notification.
A DGTR recommendation does not itself impose a customs duty. No implementing Finance Ministry or CBIC notification was identified for this story, so the proposed rates should not be treated as currently payable.
Why this matters
For hospitals, distributors and other buyers, exposure depends on the glove specification and supplier. The investigation covers medical examination gloves made of nitrile butadiene rubber latex, natural-rubber latex or a blend.
Surgical gloves are excluded, as are industrial, household, gardening and cleaning gloves. Vinyl, chlorinated, neoprene and other synthetic gloves outside the defined product scope are also excluded. Buyers need to match the precise product and producer against the final findings rather than apply the highest rate to every glove shipment.
The Big Picture
Trade duties, if notified, can change the landed cost of covered imports and the relative appeal of alternative suppliers. They do not amount to an import ban. Contract terms, inventories, sourcing choices and the final notification would affect how any additional cost reaches purchasers.
The findings do not establish a particular rise in hospital procurement costs or retail prices. A single headline rate also obscures the lower proposed Thai rates.
The Crunch
The recommendation is now public, but the implementation step remains separate. Procurement teams have a reason to review supplier exposure; a confirmed duty liability requires the government notification and its exact terms.
Leave your thoughts